[Effects of RAGE on Cell Proliferation and Tumor Growth in Pancreatic Cancer]

Area of Science:

• Molecular Biology
• Oncology
• Cancer Research

Background:

• Pancreatic cancer is a highly aggressive malignancy with limited treatment options.
• The receptor for advanced glycation end products (RAGE) is implicated in various cancers.
• Understanding RAGE's role in pancreatic cancer is crucial for developing novel therapies.

Purpose of the Study:

• To investigate the effect of RAGE on pancreatic cancer cell proliferation and tumor growth.
• To explore the impact of RAGE inhibition on key molecular markers associated with tumor progression and angiogenesis.

Main Methods:

• PANC-1 cells were transfected with short hairpin RNA (shRNA) targeting RAGE to down-regulate its expression.
• Cell proliferation was assessed using Cholecystokinin octopeptide-8 (CCK-8) assays.
• Real-time PCR and Western blot analyzed the expression of RAGE, MMP-2, MMP-9, NF-κB, and VEGF.
• Tumor growth and microvessel density were evaluated in nude mice models using immunohistochemistry.

Main Results:

• RAGE down-regulation via shRNA significantly inhibited PANC-1 cell proliferation.
• Mice xenografted with RAGE-inhibited cells exhibited reduced tumor volume and microvessel density.
• Inhibition of RAGE led to decreased expression of MMP-2, MMP-9, NF-κB, and VEGF at both mRNA and protein levels.

Conclusions:

• RAGE plays a significant role in the progression of pancreatic cancer both in vitro and in vivo.
• RAGE inhibition effectively suppresses tumor growth and angiogenesis, indicating its potential as a therapeutic target.
• Targeting RAGE may offer a novel strategy for managing pancreatic cancer by disrupting tumor progression and vascularization.